WestEnd Advisors LLC reduced its stake in UnitedHealth Group Inc (NYSE:UNH) by 4.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,312 shares of the healthcare conglomerate’s stock after selling 6,453 shares during the period. UnitedHealth Group makes up about 2.9% of WestEnd Advisors LLC’s holdings, making the stock its 23rd largest holding. WestEnd Advisors LLC’s holdings in UnitedHealth Group were worth $33,261,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in UNH. Canton Hathaway LLC acquired a new stake in UnitedHealth Group in the first quarter valued at $36,000. Truvestments Capital LLC acquired a new stake in UnitedHealth Group in the first quarter valued at $42,000. Creative Financial Designs Inc. ADV raised its stake in UnitedHealth Group by 89.6% in the first quarter. Creative Financial Designs Inc. ADV now owns 201 shares of the healthcare conglomerate’s stock valued at $50,000 after buying an additional 95 shares in the last quarter. Financial Gravity Wealth Inc. acquired a new stake in UnitedHealth Group in the first quarter valued at $58,000. Finally, Horan Capital Advisors LLC. acquired a new stake in UnitedHealth Group in the first quarter valued at $68,000. Institutional investors and hedge funds own 85.65% of the company’s stock.

Shares of UNH traded up $4.24 during midday trading on Friday, reaching $252.94. 3,362,620 shares of the stock were exchanged, compared to its average volume of 3,922,539. The firm has a 50-day simple moving average of $250.74. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.67 and a quick ratio of 0.73. UnitedHealth Group Inc has a twelve month low of $208.07 and a twelve month high of $287.94. The stock has a market cap of $240.38 billion, a P/E ratio of 18.04, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61.

UnitedHealth Group (NYSE:UNH) last posted its earnings results on Thursday, July 18th. The healthcare conglomerate reported $3.60 EPS for the quarter, topping the Zacks’ consensus estimate of $3.46 by $0.14. UnitedHealth Group had a return on equity of 25.20% and a net margin of 5.51%. The business had revenue of $60.60 billion for the quarter, compared to analysts’ expectations of $60.59 billion. During the same quarter in the previous year, the firm earned $3.14 earnings per share. The business’s revenue was up 8.0% compared to the same quarter last year. As a group, equities research analysts expect that UnitedHealth Group Inc will post 14.82 earnings per share for the current year.

In related news, Director William C. Ballard, Jr. sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $255.31, for a total transaction of $3,063,720.00. Following the transaction, the director now owns 61,309 shares of the company’s stock, valued at $15,652,800.79. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director William C. Ballard, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $239.02, for a total value of $1,195,100.00. Following the transaction, the director now directly owns 77,993 shares in the company, valued at approximately $18,641,886.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,000 shares of company stock worth $9,158,720. Corporate insiders own 0.87% of the company’s stock.

A number of analysts have weighed in on UNH shares. Morgan Stanley set a $207.00 price target on Alibaba Group and gave the company a “buy” rating in a research note on Friday, July 12th. Citigroup restated a “buy” rating on shares of Healthequity in a research note on Friday, May 10th. ValuEngine cut Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th. Royal Bank of Canada set a $311.00 price target on UnitedHealth Group and gave the company a “buy” rating in a research note on Friday, July 19th. Finally, UBS Group set a $36.00 target price on Halliburton and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $295.06.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Further Reading: How do buyers and sellers choose a strike price?

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Inc (NYSE:UNH).

Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.